Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2012; 108(06): 1165-1171
DOI: 10.1160/TH12-05-0350
DOI: 10.1160/TH12-05-0350
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism
A population-based case-control studyFinancial support:AB is a research fellow with the University of Oslo. The study was supported by grants from the southeastern Norway Health Authority, the Oslo University Hospital Trust, and the Norwegian Research Council (grant no 160805-V50). The sponsors of the study had no role in the study design;the collection, analysis, and interpretation of data;or writing, review, or approval of the manuscript. The authors are fully independent of the sponsors.
Further Information
Publication History
Received:
25 May 2012
Accepted after minor revision:
07 September 2012
Publication Date:
30 November 2017 (online)
Summary
Limited data exist on thrombophilia and the risk of venous thrombosis (VT) during pregnancy and postpartum. The objectives of the present study were to investigate the role of haemostatic risk factors for pregnancy-related VT and their phenotypic expression in deep-vein thrombosis (DVT) and pulmonary embolism (PE). Total 313 cases with objectively verified first time VT and 353 controls were selected from a source population of 377,155 women with 613,232 pregnancies. The adjusted odds ratio (aOR) for pregnancy-related VT was 1.7 (95% confidence interval [CI] 1.1–2.8) for women with factor VIII >90th percentile. The aOR for VT for endogenous thrombin potential and D-dimer values >90thpercentiles were 1.8 (95% CI 1.1–3.0) and 2.1 (95% CI 1.3–3.3), respectively. Factor IX >90thpercentile or free protein S ≤the 5th percentile increased the risk for PE, and the aORs were 2.4 (95% CI 1.1–5.0) and 3.1 (95% CI 1.3–7.2), respectively. Women carrying the factor V Leiden (F5 rs6025) polymorphism, or who had reduced sensitivity to activated protein C (aPC) in the absence of F5 rs6025, had increased risk for DVT, with unadjusted ORs 7.7 (95% CI 4.7–12.7) and 3.5 (95% CI 2.2–5.4), respectively. Women with a history of pregnancy-related VT showed activation of coagulation and had elevated factor VIII. Furthermore, high levels of factor IX and low levels of free protein S were associated with increased risk for PE, whereas aPC resistance and F5 rs6025 were risk factors for DVT and not PE.
-
References
- 1 Franchini M. Haemostasis and pregnancy. Thromb Haemost 2006; 95: 401-413.
- 2 Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168.
- 3 Berg CJ, Callaghan WM, Syverson C. et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116: 1302-1309.
- 4 Hogberg U, Innala E, Sandstrom A. Maternal mortality in Sweden, 1980-1988. Obstet Gynecol 1994; 84: 240-244.
- 5 Wildman K, Bouvier-Colle MH. Maternal mortality as an indicator of obstetric care in Europe. Br J Obstet Gynecol 2004; 111: 164-169.
- 6 Martinelli I. Thromboembolism in women. Semin Thromb Hemost 2006; 32: 709-715.
- 7 Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol 2008; 198: 233-237.
- 8 James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009; 29: 326-331.
- 9 Koster T, Blann AD, Briet E. et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
- 10 van Hylckama Vlieg A, van der Linden IK, Bertina RM. et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-3682.
- 11 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
- 12 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
- 13 van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003; 1: 2677-2678.
- 14 Tsai AW, Cushman M, Rosamond WD. et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-642.
- 15 Conard J, Horellou MH, van Dreden P. et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-20.
- 16 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
- 17 Friederich PW, Sanson BJ, Simioni P. et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-960.
- 18 Jacobsen AF, Dahm A, Bergrem A. et al. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost 2010; 8: 2443-2449.
- 19 Martinelli I, de Stefano V, Taioli E. et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791-795.
- 20 Gerhardt A, Scharf RE, Beckmann MW. et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-380.
- 21 Robertson L, Wu O, Langhorne P. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
- 22 Bergrem A, Dahm AE, Jacobsen AF, Mowinckel MC, Sandvik L, Sandset PM. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br J Haematol 2011; 154: 241-247.
- 23 Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-1375.
- 24 Makelburg AB, Veeger NJ, Middeldorp S. et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica 2010; 95: 1030-1033.
- 25 Turkstra F, Karemaker R, Kuijer PM. et al. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?. Thromb Haemost 1999; 81: 345-348.
- 26 Meyer G, Emmerich J, Helley D. et al. Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med 2001; 110: 12-15.
- 27 Margaglione M, Brancaccio V, de Lucia D. et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000; 118: 1405-1411.
- 28 de Moerloose P, Reber G, Perrier A. et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110: 125-129.
- 29 Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6: 905-912.
- 30 Bergrem A, Jacobsen EM, Skjeldestad FE. et al. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study. Thromb Res 2010; 125: e222-e227.
- 31 Trigg DE, Wood MG, Kouides PA. et al. Hormonal influences on hemostasis in women. Semin Thromb Hemost 2011; 37: 77-86.
- 32 Bloemenkamp KW, Rosendaal FR, Helmerhorst FM. et al. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80: 382-387.
- 33 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29: 125-130.
- 34 Kraaijenhagen RA, in’t Anker PS, Koopman MM. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
- 35 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
- 36 Lijfering WM, Mulder R, Ten Kate MK. et al. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood 2009; 113: 1225-1230.
- 37 Mulder R, Ten Kate MK, Kluin-Nelemans HC. et al. Low cut-off values increase diagnostic performance of protein S assays. Thromb Haemost 2010; 104: 618-625.
- 38 van Hylckama Vlieg A, Christiansen SC, Luddington R. et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007; 138: 769-774.
- 39 Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost 2002; 87: 47-51.
- 40 Lowe G, Woodward M, Vessey M. et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-535.
- 41 Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609.
- 42 Chooi CC, Gallus AS. Acute phase reaction, fibrinogen level and thrombus size. Thromb Res 1989; 53: 493-501.
- 43 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
- 44 van Stralen KJ, Doggen CJ, Bezemer ID. et al. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol 2008; 28: 1872-1877.